Document Type : Original Article


1 Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran

2 Department of Biological Sciences, Faculty of Basic Sciences, Higher Education Institute of Rab-Rashid, Tabriz, Iran

3 Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran


The effects of buprenorphine (BUP) on anxiety-like behavior and the expression of the glial fibrillary acidic protein (Gfap) and nuclear factor erythroid 2–related factor 2 (Nrf2) in methamphetamine (METH)-treated rats were investigated in this study. Twenty-eight male Wistar rats were randomly divided into four groups including control (saline), METH (10.00 mg kg-1), BUP (10.00 mg kg-1), and BUP + METH groups and treated for five days. On the final day of treatment, gene expression levels and anxiety were evaluated using elevated plus-maze (EPM). According to the results, five days of METH injection reduced open arm exploration in the EPM. In contrast, the open arm entries and the time spent in the open arms were increased in the BUP + METH group compared to the METH group. The expression levels of Gfap and Nrf2 were lower in METH-treated rats compared to controls, whereas Gfap and Nrf2 expression levels were higher in the METH+BUP-treated rats compared to the METH-treated rats, however, it was similar to the controls. These findings suggested that co-administration of BUP+METH could decrease anxiety-like behavior through increasing the activity of the antioxidant protection system and might have therapeutic potential for preventing anxiety in METH users.


  1. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, et al. Anxiety disorders among methamphetamine dependent adults: association with post-treatment functioning. Am J Addict 2010; 19(5): 385-590.
  2. Su H, Zhang J, Ren W, et al. Anxiety level and correlates in methamphetamine-dependent patients during acute withdrawal. Medicine (Baltimore) 2017; 96(15): e6434. doi: 10.1097/MD.0000000000006434.
  3. Shahidi S, Komaki A, Sadeghian R, et al. Different doses of methamphetamine alter long-term potentiation, level of BDNF and neuronal apoptosis in the hippocampus of reinstated rats. J Physiol Sci 2019; 69(2): 409-419. 
  4. Shahidi S, Mehrpour O, Sadeghian R, et al. Alteration level of hippocampus BDNF expression and long-term potentiation upon microinjection of BRL15572 hydrochloride in a rat model of methamphetamine relapse. Brain Res Bull 2019; 148: 18-24.
  5. Jones HE. Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect 2004; 2(2): 4-20. 
  6. Kantak KM, Riberdy A, Spealman RD. Cocaine-opioid interactions in groups of rats trained to discriminate different doses of cocaine. Psychopharmacology (Berl) 1999; 147(3): 257-265. 
  7. Mello NK, Negus SS. Effects of d-amphetamine and buprenorphine combinations on speedball (cocaine+heroin) self-administration by rhesus monkeys. Neuropsychopharmacology 2007; 32(9): 1985-1994.
  8. Pereira FC, Gough B, Macedo TR, et al. Buprenorphine modulates methamphetamine-induced dopamine dynamics in the rat caudate nucleus. Neurotox Res 2011; 19(1): 94-101. 
  9. Dehghan MH, Dehghan S, Jalali A, et al. Histo-pathological Effects of cumulative concentrations of buprenorphine in hippocampus of rats. AUMJ 2018; 7(2): 123-132.
  10. Yang X, Wang Y, Li Q, et al. The main molecular mechanisms underlying methamphetamine- induced neurotoxicity and implications for pharmacological treatment. Front Mol Neurosci 2018; 11: 186. doi: 10.3389/fnmol.2018.00186.
  11. Ma Q. Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 2013; 53: 401-426.
  12. Ramkissoon A, Wells PG. Methamphetamine oxidative stress, neurotoxicity, and functional deficits are modulated by nuclear factor-E2-related factor 2. Free Radic Biol Med 2015; 89: 358-368.
  13. Rammal H, Bouayed J, Younos C, et al. Evidence that oxidative stress is linked to anxiety-related behaviour in mice. Brain Behav Immun 2008; 22(8): 1156-1159.
  14. Salim S, Sarraj N, Taneja M, et al. Moderate treadmill exercise prevents oxidative stress-induced anxiety-like behavior in rats. Behav Brain Res 2010; 208(2): 545-552.
  15. Friend DM, Keefe KA. Glial reactivity in resistance to methamphetamine-induced neurotoxicity. J Neuro-chem 2013; 125(4): 566-574.
  16. Jang S, Suh SH, Yoo HS, et al. Changes in iNOS, GFAP and NR1 expression in various brain regions and elevation of sphingosine-1-phosphate in serum after immobilized stress. Neurochem Res 2008; 33(5): 842-851.
  17. Xu E, Liu J, Liu H, et al. Role of microglia in methamphetamine-induced neurotoxicity. Int J Physiol Pathophysiol Pharmacol 2017; 9(3): 84-100.
  18. Peruga I, Hartwig S, Thöne J, et al. Inflammation modulates anxiety in an animal model of multiple sclerosis. Behav Brain Res 2011; 220(1): 20-29.
  19. Glover EM, Davis M. Anxiolytic-like effects of morphine and buprenorphine in the rat model of fear-potentiated startle: tolerance, cross-tolerance, and blockade by naloxone. Psychopharmacology (Berl). 2008; 198(2): 167-180.
  20. Hatami S, Hatami H, Sheikhzade F, et al. Effect of alcoholic extract of scrophularia striata on improving spatial memory in the model of crystal meth addiction in male rats. JSSU 2020; 27(11): 2076-2090.
  21. Biala G, Kruk-Slomka M, Jozwiak K. Influence of acute or chronic calcium channel antagonists on the acquisition and consolidation of memory and nicotine-induced cognitive effects in mice. Naunyn Schmiede-bergs Arch Pharmacol 2013; 386(7): 651-664. 
  22. Etaee F, Komaki A, Faraji N, et al. The effects of cinnamaldehyde on acute or chronic stress-induced anxiety-related behavior and locomotion in male mice. Stress 2019; 22(3): 358-365.
  23. Khajehnasiri N, Dehkordi MB, Amini-Khoei H, et al. Effect of exercise intensity and duration on the levels of stress hormones and hypothalamic-pituitary-gonadal axis in adult male rats: an experimental study. Hormones (Athens) 2021; 20(3): 483-490.
  24. Shahidi S, Sadeghian R, Komaki A, et al. Intracerebro-ventricular microinjection of the 5-HT1F receptor agonist LY 344864 inhibits methamphetamine conditioned place preference reinstatement in rats. Pharmacol Biochem Behav 2018; 173: 27-35.
  25. Shahidi S, Komaki A, Sadeghian R, et al. Effect of a 5-HT1D receptor agonist on the reinstatement phase of the conditioned place preference test and hippocampal long-term potentiation in methamphetamine-treated rats.
  26. Brain Res 2018; 1698: 151-160.

Mori T, Ito S, Kita T, et al. Effects of mu-, delta- and kappa-opioid receptor agonists on methamphetamine- induced self-injurious behavior in mice. Eur J Pharmacol 2006; 532(1-2): 81-87.

  1. Miladi-Gorji H, Fadaei A, Bigdeli I. Anxiety assessment in methamphetamine - sensitized and withdrawn rats: immediate and delayed effects. Iran J Psychiatry 2015; 10(3): 150-157.
  2. Pometlová M, Nohejlová-Deykun K, Slamberová R. Anxiogenic effect of low-dose methamphetamine in the test of elevated plus-maze. Prague Med Rep 2012; 113(3):223-230.
  3. Kitanaka N, Kitanaka J, Tatsuta T, et al. Withdrawal from fixed-dose injection of methamphetamine decreases cerebral levels of 3-methoxy-4-hydroxy-phenylglycol and induces the expression of anxiety-related behavior in mice. Neurochem Res 2010; 35(5): 749-760.
  4. Ahmadi J, Jahromi Anxiety treatment of opioid dependent patients with buprenorphine: a randomized, double-blind, clinical trial. Indian J Psychol Med 2017; 39(4): 445-449.
  5. Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001; 297(2): 688-695.
  6. Wang YJ, Hang A, Lu YC, et al. κ Opioid receptor activation in different brain regions differentially modulates anxiety-related behaviors in mice. Neuropharmacology 2016; 110(Pt A): 92-101.
  7. Etaee F, Asadbegi M, Taslimi Z, et al. The effects of methamphetamine and buprenorphine, and their interaction on anxiety-like behavior and locomotion in male rats. Neurosci Lett 2017; 655: 172-178.
  8. Ali SF, Jiang H, Rongzhu L, et al. Methamphetamine dysregulates redox status in primary rat astrocyte and mesencephalic neuronal cultures. Am J Neuroprot Neuroregen 2009; 1(1): 52-59.
  9. Pacchioni AM, Vallone J, Melendez RI, et al. Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity. Brain Res 2007; 1127(1): 26-35.
  10. Guilarte TR, Nihei MK, McGlothan JL, et al. Meth-amphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 2003; 122(2): 499-513.
  11. Thomas DM, Kuhn Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J Neurochem 2005; 92(4): 790-797.
  12. Kitamura O, Takeichi T, Wang EL, et al. Microglial and astrocytic changes in the striatum of methamphetamine Leg Med (Tokyo) 2010; 12(2): 57-62.
  13. Fukumura M, Cappon GD, Pu C, et al. A single dose model of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res 1998; 806(1): 1-7.
  14. Granado N, Lastres-Becker I, Ares-Santos S, et al. Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Glia 2011; 59(12): 1850-1863.